Search Result

Results for "

EZH2 degrader

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (6) Bcl-2 Family (1) Caspase (1) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (11) Histone Methyltransferase (51) HyT (1) IAP (2) Ligands for Target Protein for PROTAC (4) PARP (1) PROTAC Linkers (1) PROTACs (44)
By Research Areas:	Cancer (51) Inflammation/Immunology (1)
Click Chemistry:	Azide (3)

Inhibitors & Agonists

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147525

*PROTAC EZH2* Degrader-1** 1 Publications Verification	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-1 (Compound 150d), a potent PROTAC EZH2 Degrader, exerts inhibitory effect on EZH2 methyltransferase activity with the IC₅₀ of 2.7 nM. EZH2 plays an important role in many tumorigenesis and development processes .

HY-133129

MS1943 4 Publications Verification	HyT Histone Methyltransferase Apoptosis	Inflammation/Immunology Cancer
MS1943 is an orally active selective HyT degrader of *EZH2* that effectively reduces *EZH2* levels in cells. MS1943 has anticancer activity and exhibits cytotoxic effects in a variety of TNBC cells while sparing normal cells. In addition, MS1943 maintains high potency (IC₅₀=120 nM) in inhibiting EZH2 methyltransferase activity and is highly selective for *EZH2. (Structure Note: RED, EZH2* ligand (HY-148458); Blue, Hyt (HY-W001578)) .

HY-148333

MS177 3 Publications Verification	PROTACs Histone Methyltransferase Apoptosis	Cancer
MS177 is an effective and fast-acting *EZH2* degrader. MS177 is a PROTAC that consists of a CRBN ligand, linker, and a potent enzymatic EZH2 inhibitor C24 (C24 IC₅₀): 12 nM). MS177 effectively depletes both canonical EZH2-PRC2 and noncanonical EZH2-cMyc complexes. MS177 induces leukaemia cell growth inhibition, apoptosis and cell cycle progression arrest .

HY-157164

*PROTAC EZH2* Degrader-2** 1 Publications Verification	PROTACs Histone Methyltransferase Apoptosis	Cancer
PROTAC EZH2 Degrader-2 is a PROTAC *EZH2* inhibitor. PROTAC EZH2 Degrader-2 degrades *EZH2* in SU-DHL-6 cells in a dose-dependent manner. PROTAC EZH2 Degrader-2 induces apoptosis and reduces mitochondrial membrane potential in SU-DHL-6 cells. PROTAC EZH2 Degrader-2 has anti-cancer and anti-proliferative activity .

HY-147091

Tazemetostat de(methyl morpholine)-COOH	Ligands for Target Protein for PROTAC	Cancer
Tazemetostat de(methyl morpholine)-COOH (compound 7) is a ligand for the PROTAC target protein *EZH2, which can be used to synthesis of EZH2* degraders (PROTACs). *EZH2* degraders have potent cell viability inhibition in diffuse large B-cell lymphoma (DLBCL) and other subtypes of lymphoma .

HY-162250

MS8847	PROTACs Histone Methyltransferase	Cancer
MS8847 is a PROTAC degrader and antiproliferative agent targeting *EZH2* (DC₅₀=34.4 nM in EOL-1 MLL-rAML cells). MS8847 recruits the E3 ligase von Hippel-Lindau (VHL) to mediate the degradation of EZH2 via the ubiquitin-proteasome system. MS8847 induces antiproliferative effects in MLL-rearranged acute myeloid leukemia cells and inhibits the growth of triple-negative breast cancer cell lines or 3D triple-negative breast cancer models. MS8847 is applicable to research related to MLL-rearranged acute myeloid leukemia and triple-negative breast cancer .

HY-119198

NSC745885	Apoptosis Histone Methyltransferase	Cancer
NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of *EZH2* via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers .

HY-101508

GNA002	Histone Methyltransferase	Cancer
GNA002 is a highly potent, specific and covalent *EZH2* (Enhancer of zeste homolog 2) inhibitor with an IC₅₀ of 1.1 μM. GNA002 can specifically and covalently bind to Cys668 within the EZH2-SET domain, triggering EZH2 degradation through COOH terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination. GNA002 efficiently reduces EZH2-mediated H3K27 trimethylation, reactivates polycomb repressor complex 2 (PRC2)-silenced tumor suppressor genes .

HY-148334

MS8815	PROTACs Histone Methyltransferase	Cancer
MS8815 is a selective enhancer of zeste homolog 2 (EZH2) PROTAC degrader. MS8815 has inhibition activity for EZH2 with an IC₅₀ value of 8.6 nM. MS8815 can be used for the research of triple-negative breast cancer (TNBC) .

HY-157844

NUCC-0226272	PROTACs Histone Methyltransferase	Cancer
NUCC-0226272 is a potent PROTAC that targets *EZH2* for degradation. NUCC-0226272 has anti-proliferative effect. NUCC-0226272 has the potential for cancer research .

HY-W014099

Boc-NH-C4-acid	PROTAC Linkers	Cancer
Boc-NH-C4-acid is a PROTAC linker, which belongs to a Alkyl/ether linker. Boc-NH-C4-acid can be used in the synthesis of the compound PROTAC1, and specifically degrades EED, EZH2, and SUZ12 in the PRC2 Complex.

HY-168131

*PROTAC EZH2* Degrader-3**	PROTACs Histone Methyltransferase Apoptosis	Cancer
PROTAC EZH2 Degrader-3 (compound ZJ-20) is a *EZH2* PROTAC degrader. PROTAC EZH2 Degrader-3 (5 μM, 24 h) not only potently inhibits the expression of EZH2 protein, but also had a strong inhibits effect on the expression levels of other subunits of PRC2 as well as H3k27me3 protein. PROTAC EZH2 Degrader-3 shows anti-proliferative activity and blocks the cell cycle in the G0-G1 phase and induces cell apoptosis((Blue: cereblon ligand Pomalidomide (HY-10984), Black: linker HY-W361751；Pink: EZH2 inhibitor Tazemetostat (HY-13803)) .

HY-158239

MS181	PROTACs E1/E2/E3 Enzyme	Cancer
MS181 (compound 1) is a potent cereblon (CRBN)-recruiting and EED-binding polycomb repressive complex 1 (PRC1) PROTAC degrader. MS181 decreases the expression of EED, EZH2, SUZ12, BMI1 and RING1B. MS181 shows antiproliferative activity (Strtucture Note: Red, EED binder (HY-158771); Blue, CRBN ligand (HY-41547); Black, Linker HY-131717) .

HY-181326

*PROTAC EZH2* Degrader-25**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-25 (compound 10) is an *EZH2*-targeting PROTAC degrader. PROTAC EZH2 Degrader-25 triggers ubiquitination and subsequent proteasomal degradation of *EZH2. PROTAC EZH2* Degrader-25 can be used for the research of lymphoma .

HY-181411

*PROTAC EZH2* Degrader-42**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-42 (compound 57) is an *EZH2*-targeting PROTAC degrader and antiproliferative agent. PROTAC EZH2 Degrader-42 induces cIAP-mediated ubiquitination and subsequent proteasomal degradation of *EZH2. PROTAC EZH2* Degrader-42 can be used for the research of lymphoma .

HY-181308

*PROTAC EZH2* Degrader-13**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-13 is an *EZH2*-targeting PROTAC with an IC₅₀ of 2.70 nM. PROTAC EZH2 Degrader-13 exerts antiproliferative effects in cancer cells. PROTAC EZH2 Degrader-13 can be used for the research of cancer .

HY-181323

*PROTAC EZH2* Degrader-22**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-22 (compound 7) is a PROTAC protein degrader targeting *EZH2. PROTAC EZH2* Degrader-22 is applicable to cancer-related research .

HY-181305

*PROTAC EZH2* Degrader-10**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-10 is a selective PROTAC protein degrader targeting *EZH2. PROTAC EZH2* Degrader-10 can be used for the research of cancer .

HY-181391

*PROTAC EZH2* Degrader-34**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-34 (compound E7 (13)) is an *EZH2*-target PROTAC degrader with a human *EZH2* IC₅₀ of 6.30 μM. PROTAC EZH2 Degrader-34 can be used for the research of pfeiffer cancer, prostate cancer .

HY-181331

*PROTAC EZH2* Degrader-27**	PROTACs Histone Methyltransferase	Others
PROTAC EZH2 Degrader-27 is a *EZH2* PROTAC inhibitor with an IC₅₀ of 4.00 nM against *EZH2. PROTAC EZH2* Degrader-27 inhibits methyltransferase activity by interacting with the SET domain of *EZH2* .

HY-181309

*PROTAC EZH2* Degrader-15**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-15 (compound 5) is an *EZH2*-targeting PROTAC. PROTAC EZH2 Degrader-15 functionally inhibits *EZH2* methyltransferase activity .

HY-181410

*PROTAC EZH2* Degrader-41**	PROTACs Histone Methyltransferase IAP	Cancer
PROTAC EZH2 Degrader-41 is an *EZH2*-targeting PROTAC and cIAP E3 ubiquitin ligase recruiter. PROTAC EZH2 Degrader-41 induces *EZH2* degradation via ubiquitination and proteasomal breakdown. PROTAC EZH2 Degrader-41 exerts antiproliferative effects in lymphoma cells. PROTAC EZH2 Degrader-41 can be used for the research of lymphoma .

HY-181324

*PROTAC EZH2* Degrader-23**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-23 (compound 8) is a PROTAC protein degrader targeting *EZH2* with a target IC₅₀ of 30.00 nM. PROTAC EZH2 Degrader-23 inhibits *EZH2* methyltransferase activity via interaction with the *EZH2* SET domain .

HY-181333

*PROTAC EZH2* Degrader-38**	PROTACs Histone Methyltransferase	Others
PROTAC EZH2 Degrader-38 (Compound 17) is a *EZH2* PROTAC degrader with an IC₅₀ of 165.00 nM. PROTAC EZH2 Degrader-38 functionally inhibits the methyltransferase activity of *EZH2* and competitively binds to the SAM-binding pocket of the *EZH2* SET domain .

HY-181319

*PROTAC EZH2* Degrader-21**	PROTACs Histone Methyltransferase IAP	Cancer
PROTAC EZH2 Degrader-21 is an EZH2 degrader developed based on PROTAC technology. PROTAC EZH2 Degrader-21 induces the degradation of the target protein EZH2 via specific recruitment of the cIAP E3 ligase. PROTAC EZH2 Degrader-21 exhibits significant inhibitory activity in a variety of lymphoma cell lines. PROTAC EZH2 Degrader-21 can be used for research on the pathogenesis of lymphoma .

HY-181334

*PROTAC EZH2* Degrader-39**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-39 (compound 18) is a PROTAC protein degrader targeting *EZH2* with a target IC₅₀ of 61.00 nM. PROTAC EZH2 Degrader-39 functionally inhibits *EZH2* methyltransferase activity .

HY-181325

*PROTAC EZH2* Degrader-24**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-24 (compound 9) is an *EZH2*-targeting PROTAC with *EZH2* methyltransferase inhibitory activity .

HY-181306

*PROTAC EZH2* Degrader-11**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-11 (compound 2) is a *EZH2*-targeting PROTAC protein degrader. PROTAC EZH2 Degrader-11 reduces tumor size and viability in 3D spheroid models. PROTAC EZH2 Degrader-11 can be used for the research of cancer .

HY-181320

*PROTAC EZH2* Degrader-19**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-19 (compound 6) is a is a PROTAC protein degrader targeting *EZH2* with an IC₅₀ of 15.00 nM. PROTAC EZH2 Degrader-19 induces strong degradation of all PRC2 subunits (EZH2, SUZ12, EED, RbAp48) in a concentration- and time-dependent manner.PROTAC EZH2 Degrader-19 exhibits antiproliferative effects in cancer cells.PROTAC EZH2 Degrader-19 can be used for the research of cancer .

HY-181327

*PROTAC EZH2* Degrader-26**	PROTACs Histone Methyltransferase	Others
PROTAC EZH2 Degrader-26 (compound 11) is an *EZH2* degrader developed based on PROTAC technology. PROTAC EZH2 Degrader-26 has an IC₅₀ of 5.80 nM against *EZH2. PROTAC EZH2* Degrader-26 exhibits micromolar-level enzyme inhibitory activity against EZH1, with an EZH1 IC₅₀ of 0.06 μM .

HY-156292

IHMT-EZH2-426	Histone Methyltransferase	Cancer
IHMT-EZH2-426 (compound 38) is an effective covalent *EZH2* degrader, with IC₅₀ values of 1.3 nM, 1.2 nM, and 1.7-3.5 nM for EZH2 wild type, EZH2-A687V, and EZH2-Y641F/Y641N/Y641S, respectively. IHMT-EZH2-426 reduces H3K27me3 and EZH2 levels and shows effective anti-proliferative effects in B-cell lymphoma and TNBC cell lines.

HY-181332

*PROTAC EZH2* Degrader-37**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-37 (compound 16) is a PROTAC protein degrader targeting *EZH2* with a target IC₅₀ of 144 nM. PROTAC EZH2 Degrader-37 is applicable to lymphoma-related research .

HY-181392

*PROTAC EZH2* Degrader-35**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-35 (compound U3i (44)) is a PROTAC protein degrader targeting *EZH2* with a human *EZH2* K_a of 16.19 nM. PROTAC EZH2 Degrader-35 exhibits antiproliferative activity in triple-negative breast cancer cells and minimal cytotoxicity in normal human epithelial, hepatic, renal cells.PROTAC EZH2 Degrader-35 can be used for the research of triple-negative breast cancer .

HY-181300

*PROTAC EZH2* Degrader-17**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-17 (compound 52) is a PROTAC protein degrader targeting *EZH2* with an antiproliferative IC₅₀ of 18.32 μM in lymphoma cells. PROTAC EZH2 Degrader-17 exhibits antiproliferative activity against lymphoma cells. PROTAC EZH2 Degrader-17 can be used for the research of lymphoma .

HY-181354

*PROTAC EZH2* Degrader-36**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-36 (compound 15) is a PROTAC protein degrader targeting *EZH2* with a target IC₅₀ of 16.00 nM.PROTAC EZH2 Degrader-36 applicable to lymphoma-related research .

HY-181307

*PROTAC EZH2* Degrader-12**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-12 (compound 3) is a CRBN-recruiting PROTAC-based *EZH2* degrader with an *EZH2* IC₅₀ of 3.90 nM and EZH1 IC₅₀ of 5.24 μM .

HY-181318

*PROTAC EZH2* Degrader-20**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-20 (compound 54) is an *EZH2*-target PROTAC degrader with antiproliferative activity and IC₅₀ values of about 10 μM against lymphoma cells. PROTAC EZH2 Degrader-20 can be used for the research of lymphoma .

HY-181301

*PROTAC EZH2* Degrader-18**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-18 (compound E-CH2-B4) is a PROTAC protein degrader targeting *EZH2. PROTAC EZH2* Degrader-18 is applicable to lymphoma-related research .

HY-179499

*PROTAC EZH2* Degrader-9**	PROTACs Histone Methyltransferase Apoptosis	Cancer
PROTAC EZH2 Degrader-9 is orally active EZH2 PROTAC degrader degrading *EZH2* via the ubiquitin-proteasome pathway. PROTAC EZH2 Degrader-9 downregulates PRC2 core subunits and potent inhibition of H3K27me3 without affecting common CRBN neosubstrates while it was selective over GSp'T1 and ikZF1/3. PROTAC EZH2 Degrader-9 exhibits potent antiproliferative activity against multiple cancer cell lines by inducing cell cycle and apoptosis. PROTAC EZH2 Degrader-9 reverses PRC2-mediated gene silencing and inhibiting *EZH2* non-catalytic target gene activation. PROTAC EZH2 Degrader-9 can be used for leukemia, lymphoma, and non-small cell lung cancer research .

HY-181412

*PROTAC EZH2* Degrader-43**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-43 (compound 59) is a PROTAC protein degrader targeting *EZH2* with an IC₅₀ of 21.73 μM against SU-DHL-6 cells. PROTAC EZH2 Degrader-43 can be used for the research of lymphoma .

HY-181355

*PROTAC EZH2* Degrader-28**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-28 (compound 66) is a PROTAC protein degrader targeting *EZH2* with an IC₅₀ of 16.2 μM against diffuse large B-cell lymphoma cells. PROTAC EZH2 Degrader-28 can be used for the research of lymphoma .

HY-181296

*PROTAC EZH2* Degrader-16**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-16 (compound 51) is a PROTAC protein degrader targeting *EZH2* with an IC₅₀ of 13.74 μM in SU-DHL-6 cells. PROTAC EZH2 Degrader-16 exerts antiproliferative activity against diffuse large B-cell lymphoma cells. PROTAC EZH2 Degrader-16 can be used for the research of diffuse large B-cell lymphoma .

HY-181414

*PROTAC EZH2* Degrader-45**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-45 (compound 61) is a PROTAC protein degrader targeting *EZH2* with an IC₅₀ of 22.97 μM in SU-DHL-6 cells. PROTAC EZH2 Degrader-45 can be used for the research of diffuse large b-cell lymphoma .

HY-181409

*PROTAC EZH2* Degrader-40**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-40 (compound 56) is a PROTAC protein degrader targeting *EZH2* with an IC₅₀ of 15.35 μM against SU-DHL-6 cells. PROTAC EZH2 Degrader-40 can be used for the research of diffuse large B-cell lymphoma .

HY-181359

*PROTAC EZH2* Degrader-30**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-30 (compound 67) is ais a PROTAC protein degrader targeting *EZH2* with an IC₅₀ of 6.22 μM against SU-DHL-6 cells. PROTAC EZH2 Degrader-30 can be used for the research of diffuse large B-cell lymphoma .

HY-181357

*PROTAC EZH2* Degrader-29**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-29 (compound 66) is a is a PROTAC protein degrader targeting *EZH2* with an IC₅₀ of 24.53 μM against diffuse large B-cell lymphoma cells. PROTAC EZH2 Degrader-29 can be used in studies related to diffuse large B-cell lymphoma .

HY-181360

*PROTAC EZH2* Degrader-31**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-31(compound 69) is a PROTAC protein degrader targeting *EZH2, with antiproliferative IC₅₀* values of 3.63 μM in lSU-DHL-6 cells and 8.74 μM in HBL-1 cells. PROTAC EZH2 Degrader-31 can be used for the research of lymphoma .

HY-181413

*PROTAC EZH2* Degrader-44**	PROTACs Histone Methyltransferase Bcl-2 Family Caspase PARP	Cancer
PROTAC EZH2 Degrader-44 (compound 60) is a highly efficient PROTAC degrader targeting the *EZH2-*PRC2 complex. By recruiting the CRBN E3 ligase and relying on the proteasome system, PROTAC EZH2 Degrader-44 simultaneously induces the degradation of core components EZH2, SUZ12 and EED, thereby significantly reducing the levels of H3K27me3 and CARM1. PROTAC EZH2 Degrader-44 exerts antiproliferative effects through a dual mechanism: on the one hand, it triggers mitochondrial dysfunction leading to decreased membrane potential; on the other hand, it strongly promotes apoptosis by regulating Bcl-2 family proteins (upregulating Bax, Caspase-3 and PARP, and downregulating Bcl-2). PROTAC EZH2 Degrader-44 exhibits only extremely low cytotoxicity in human normal mammary epithelial, liver and kidney cells, showing a favorable safety window. PROTAC EZH2 Degrader-44 is an ideal tool molecule for exploring the mechanisms of targeted therapy for triple-negative breast cancer .

HY-181295

*PROTAC EZH2* Degrader-14**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-14 is an *EZH2* PROTAC degrader, with an IC₅₀ of 18.21 μM against diffuse large B-cell lymphoma cells, and exhibits no antiproliferative activity against non-target cells at concentrations up to 30.00 μM. PROTAC EZH2 Degrader-14 can be used in studies related to diffuse large B-cell lymphoma .

HY-178694

DC-PRC2in-01	Histone Methyltransferase	Cancer
DC-PRC2in-01 is a potent EZH2-EED interaction inhibitor with an IC₅₀ of 4.21 μM and a K_d of 4.56 μM. DC-PRC2in-01 disrupts the EZH2-EED interaction, leading to degradation of PRC2 core proteins and decrease of H3K27me3 levels, inhibition of PRC2-driven lymphoma cell proliferation, and cell cycle arrest. DC-PRC2in-01 can be used for the research of PRC2-related cancers, such as Diffuse Large B-cell Lymphoma (DLBCL) and follicular lymphoma (FL) .

Cat. No.	Product Name		Classification

HY-181356

(S,R,S,R)-AHPC-Me-CO-C7-N3		Azide
(S,R,S,R)-AHPC-Me-CO-C7-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S,R)-AHPC-Me based VHL ligand and a linker used in PROTAC technology. (S,R,S,R)-AHPC-Me-CO-C7-N3 can be connected to the ligand for protein by a linker to form PROTAC EZH2 Degrader-28 (HY-181355) .

HY-181358

(4R,5S)-Nutlin carboxylic acid-NHC2-PEG1-N3		Azide
(4R,5S)-Nutlin carboxylic acid-NHC2-PEG1-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (4R,5S)-Nutlin carboxylic acid based MDM2 ligand and a linker used in PROTAC technology. (4R,5S)-Nutlin carboxylic acid-NHC2-PEG1-N3 can be connected to the ligand for protein by a linker to form PROTAC EZH2 Degrader-29 (HY-181357) .

HY-180924

(4R,5S)-Nutlin carboxylic acid-NHC2-PEG2-N3		Azide
(4R,5S)-Nutlin carboxylic acid-NHC2-PEG2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (4R,5S)-Nutlin carboxylic acid based MDM2 ligand and a linker used in PROTAC technology. (4R,5S)-Nutlin carboxylic acid-NHC2-PEG1-N3 can be connected to the ligand for protein by a linker to form PROTAC EZH2 Degrader-30 (HY-181359) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: